Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

1 'Strong Buy' Dividend Stock to Buy and Hold

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

What is behind the insulin shortage in the US?

Pharma companies are slashing insulin production in favour of more lucrative weight-loss drugs.

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

The Guardian - UK

Stocks Sink on Concern the Fed Will Keep Interest Rates Higher for Longer

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.57%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.92%. US stock indexes Tuesday finished sharply lower. Signs of persistent wage pressure pushed bond...

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stock Market Today: Stocks Sell Off Ahead of Fed Decision

Stocks sold off sharply Tuesday as anxiety set in ahead of Wednesday's policy statement from the Federal Reserve.

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Analysts Expect This 'Strong Buy' Weight-Loss Stock to Double

Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.

Zepbound Shows Promise In Treating Sleep Apnea

Zepbound Shows Promise In Treating Sleep Apnea

Eli Lilly's Zepbound drug shows promise in treating obstructive sleep apnea by reducing symptoms and promoting weight loss.

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Study: ‘gamechanger’ diabetes drugs cost up to 400 times more than needed

Drug companies urged to ‘release stranglehold’ on medicines such as Ozempic and Trulicity, as millions are priced out of treatment

The Guardian - UK

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

Alzheimer’s ‘breakthrough’ stalls: why a much-hyped drug is facing approval delays

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say

The Guardian - AU

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

Stocks Give Up Early Gains and Close Lower as Chip Stocks Retreat

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.18% and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.53%. Stock indexes on Friday gave up early gains and closed moderately lower. Stocks on...

Stocks Slide After U.S. Unemployment Report

Stocks Slide After U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. Stock indexes are lower this afternoon, after the S&P 500 and Nasdaq 100 posted new...

Get all your
news in one place.

100’s of premium titles.
One news app.

After a Morning Rally, Stocks Slide This Afternoon After Digesting the U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) is down -0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.82%. Stock indexes are lower this afternoon, after the S&P 500 and Nasdaq 100 posted new...

S&P 500 and Nasdaq 100 Post Record Highs on Fed-Friendly U.S. Unemployment Report

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.27%. Stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.29%. Stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

International Business Times

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Get all your
news in one place.

100’s of premium titles.
One news app.

Stocks Climb on Lower U.S. and European Bond Yields

The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.61%. Stock indexes this morning are seeing support from a decline in the 10-year...

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

International Business Times

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

The Guardian - US

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

As Tesla stock continues to underperform - now down more than 22% year-to-date - here are 3 mega-cap companies worthy of replacing the beleaguered EV giant in the elite group of mega-cap stocks known as the Magnificent Seven.

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

1 … 17 18 19 20

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Federal Reserve

the Wall Street Journal

Warner Bros Discovery

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

334,687 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play